They additionally performed an individual biomarker power discrimination with newly recruited glaucoma patients and found APOA4 yielded the best performance correctly discriminating 97% of glaucoma patients from healthy subjects with a sensitivity of 100% and a specificity of 95% (Table 2). This evidence concerns the gene APOA4 and glaucoma.